Last reviewed · How we verify
ABP 798
ABP 798 is a bispecific antibody that simultaneously engages CD3 on T cells and PMEL (gp100) on melanoma cells to redirect immune attack against melanoma tumors.
ABP 798 is a bispecific antibody that simultaneously engages CD3 on T cells and PMEL (gp100) on melanoma cells to redirect immune attack against melanoma tumors. Used for Metastatic melanoma (PMEL-positive).
At a glance
| Generic name | ABP 798 |
|---|---|
| Also known as | biosimilar to rituximab |
| Sponsor | Amgen |
| Drug class | Bispecific T-cell engager (BiTE) |
| Target | CD3 / PMEL (gp100) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABP 798 functions as a T-cell engager by bridging cytotoxic T lymphocytes to melanoma cells expressing PMEL antigen. This bispecific design brings T cells into close proximity with tumor cells, triggering T-cell activation and cytotoxic killing of melanoma cells. The mechanism leverages the body's own immune system to target and eliminate melanoma tumors.
Approved indications
- Metastatic melanoma (PMEL-positive)
Common side effects
- Cytokine release syndrome
- Fatigue
- Pyrexia
- Infusion-related reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 798 CI brief — competitive landscape report
- ABP 798 updates RSS · CI watch RSS
- Amgen portfolio CI